Peer-reviewed literature indexed on PubMed Characterizes ipamorelin's selective GHS-R1a agonism with minimal effect on cortisol or prolactin
Lixisenatide (Lyxumia) is a daily GLP-1 receptor agonist available in the UK
I use dual incretins quite often in my type one diabetic patients who have obesity and it works beautifully It lessens their insulin requirements Something about that GIP jumpstarts that sluggish pancreas and beta cells However, patients are explicitly told they need to stay on their insulin, watch their sugars closely with CGM and they totally understand
Its efficacy extends beyond appetite suppression
We are excited to share that the Zepbound single-dose vials are now here, further delivering on our promise to increase supply of Zepbound in the U.S., Patrik Jonsson, Lilly executive vice president and president of Lilly Cardiometabolic Health and Lilly USA, said in the statement
Dont worry yet my surgical friends, but more effective peptide-based medicines are on the way #endocrinologyrocks In #obese individuals without #diabetes, #semaglutide, with diet & exercise, resulted in significantly greater #weightloss over 52 weeks than placebo and liraglutidefindings from a phase 2, RCT #obesity hubs.ly/H0dqCsT0
